Phathom Pharmaceuticals Inc
NASDAQ:PHAT
| Market Cap (Intraday) | 413.69M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $10.46 |
| 50-Day MA | $8.91 |
| 200-Day MA | $13.98 |
Phathom Pharmaceuticals Inc Stock, NASDAQ:PHAT
100 Campus Drive, Suite 102, Florham Park, New Jersey 07932
United States of America
Phone: +1.877.742.8466
Number of Employees: 77
Description
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. Its product candidate vonoprazan is an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.